The α-synuclein tetramer:monomer ratio was further diminished in a G51D patient who had already developed PD clinically (REM sleep disorder, dementia, rigor, akinesia, dyskinesia, hallucinations) compared to non-symptomatic G51D carriers and controls (Fig. 2A,B). This evidence concerns the gene SNCA and Parkinson disease.